Skip to main content
    I

    Imunon Inc (IMNN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.59
    -0.04 (-5.56%)

    Market Cap: $4.08M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Imunon Inc (IMNN) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Imunon (IMNN) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Imunon reported EPS of -$0.64, in line with the -$0.64 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    51%(20/39)
    Avg Surprise
    -10.47%

    Upcoming Estimates

    Reports Mar 29, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.51
    Range-$0.72 - -$0.25
    7 analysts
    Revenue Consensus
    N/A
    RangeN/A
    6 analysts

    Next Report

    IMNN has an expected report date of Mar 29, 2027.

    IMNN Earnings Call

    The latest IMNN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, IMNN beat 20, missed 17 and matched 2. The widest gap in the table came in the quarter ended Dec 31, 2021, when EPS landed 302.22% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.64-$0.64-$0.71 - -$0.450.00%In lineN/A4N/ANov 12, 2026N/A
    Jun 30, 2026-$0.54-$0.94N/A+42.55%BeatN/A40 up, 0 downAug 11, 2026N/A
    Mar 31, 2026-$0.84-$1.28-$1.30 - -$1.25+34.38%BeatN/A30 up, 0 downMay 12, 2026N/A
    Dec 31, 2025-$1.30-$1.82-$3.45 - -$1.22+28.57%BeatN/A41 up, 0 downMar 31, 2026N/A
    Sep 30, 2025-$1.16-$1.82-$1.95 - -$1.70+36.26%BeatN/A21 up, 0 downNov 13, 2025N/A
    Jun 30, 2025-$1.87-$4.34-$8.40 - -$3.45+56.91%BeatN/A42 up, 0 downAug 5, 2025N/A
    Mar 31, 2025-$3.65-$4.66-$6.45 - -$4.20+21.67%BeatN/A40 up, 0 downMay 12, 2025N/A
    Dec 31, 2024-$0.25-$0.36-$0.40 - -$0.32+30.56%BeatN/A20 up, 0 downFeb 27, 2025$727160
    Sep 30, 2024-$4.43-$5.35-$7.35 - -$4.65+17.20%BeatN/A40 up, 0 downNov 7, 2024N/A
    Jun 30, 2024-$6.65-$6.65N/A0.00%In lineN/A30 up, 0 downAug 14, 2024N/A
    Mar 31, 2024-$6.78-$7.39-$10.19 - -$7.20+8.25%BeatN/A30 up, 0 downMay 13, 2024N/A
    Dec 31, 2023-$0.52-$0.41-$0.41 - -$0.41-26.83%MissN/A10 up, 0 downMar 28, 2024$7.05M
    Sep 30, 2023-$4.83-$7.30N/A+33.84%BeatN/A30 up, 0 downNov 14, 2023N/A
    Jun 30, 2023-$7.46-$7.70N/A+3.12%BeatN/A20 up, 0 downAug 10, 2023N/A
    Mar 31, 2023-$8.87-$8.09N/A-9.64%MissN/A30 up, 0 downMay 11, 2023N/A
    Dec 31, 2022-$1.61-$0.85-$0.90 - -$0.79-89.41%MissN/A30 up, 0 downMar 30, 2023$125000
    Sep 30, 2022-$11.35-$10.30N/A-10.19%MissN/A30 up, 0 downNov 14, 2022$125000
    Jun 30, 2022-$11.35-$11.80N/A+3.81%BeatN/AN/AN/AAug 15, 2022$125000
    Mar 31, 2022-$23.74-$13.30N/A-78.50%MissN/AN/AN/AMay 16, 2022$125000
    Dec 31, 2021-$3.62-$0.90N/A-302.22%MissN/AN/AN/AMar 31, 2022$125000
    Sep 30, 2021-$11.74-$16.63N/A+29.40%BeatN/AN/AN/ANov 15, 2021$125000
    Jun 30, 2021-$0.90-$1.20N/A+25.00%BeatN/AN/AN/AAug 12, 2021$125000
    Mar 31, 2021-$1.35-$0.06N/AN/AN/AN/AN/AN/AMay 14, 2021$125000
    Dec 31, 2020-$9.78-$25.43N/A+61.54%BeatN/AN/AN/AMar 19, 2021$125000
    Sep 30, 2020-$46.96-$25.43N/A-84.66%MissN/AN/AN/ANov 16, 2020$125000
    Jun 30, 2020-$35.22-$29.35N/A-20.00%MissN/AN/AN/AAug 14, 2020$125000
    Mar 31, 2020-$3.00-$2.55N/A-17.65%MissN/AN/AN/AMay 15, 2020$125000
    Dec 31, 2019-$19.57-$39.13N/A+49.99%BeatN/AN/AN/AMar 25, 2020$125000
    Sep 30, 2019-$48.91-$52.83N/A+7.42%BeatN/AN/AN/ANov 14, 2019$125000
    Jun 30, 2019-$56.74-$64.57N/A+12.13%BeatN/AN/AN/AAug 14, 2019$125000
    Mar 31, 2019-$23.48-$48.91N/A+51.99%BeatN/AN/AN/AMay 15, 2019$125000
    Dec 31, 2018-$4.20-$2.05N/A-104.88%MissN/AN/AN/AMar 29, 2019$125000
    Sep 30, 2018-$50.87-$43.04N/A-18.19%MissN/AN/AN/ANov 14, 2018$125000
    Jun 30, 2018-$90.00-$52.83N/A-70.36%MissN/AN/AN/AAug 14, 2018$125000
    Mar 31, 2018-$48.91-$58.70N/A+16.68%BeatN/AN/AN/AMay 11, 2018$125000
    Dec 31, 2017-$4.68-$4.57N/A-2.41%MissN/AN/AN/AMar 27, 2018$125000
    Sep 30, 2017-$136.96-$109.57N/A-25.00%MissN/AN/AN/ANov 14, 2017$125000
    Jun 30, 2017-$154.57-$74.35N/A-107.90%MissN/AN/AN/AAug 14, 2017$125000
    Mar 31, 2017-$328.70-$301.31N/A-9.09%MissN/AN/AN/AMay 12, 2017$125000
    Dec 31, 2016-$39.90-$38.85N/A-2.70%MissN/AN/AN/AMar 16, 2017$125000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$7.98, after -$18.11 the year before. It was -$1,847.74 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$7.98N/A
    Dec 31, 2024-$18.11N/A
    Dec 31, 2023-$21.68N/A
    Dec 31, 2022-$48.05N/A
    Dec 31, 2021-$17.61N/A
    Dec 31, 2020-$94.96N/A
    Dec 31, 2019-$148.70N/A
    Dec 31, 2018-$193.98N/A
    Dec 31, 2017-$624.91N/A
    Dec 31, 2016-$1,847.74N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,100 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,1147
    2026Q2Jun 30, 20264,8979
    2026Q1Mar 31, 20263,9759
    2025Q4Dec 31, 20254,45910
    2025Q3Sep 30, 20256,4289
    2025Q2Jun 30, 20255,00210
    2025Q1Mar 31, 20253,0657
    2024Q4Dec 31, 20247,58111

    2026Q3 Earnings Call

    Opening remarks

    Valter Pinto Managing Director, KCSA Strategic Communications Thank you, operator, and good morning. Welcome to the Imunon third quarter 2026 financial results and business update conference call. Joining us today are Dr. Stacy Lindborg, President and Chief Executive Officer; Dr. Douglas Faller, Executive Vice President and Chief Medical Officer; and Josh Blacher, Interim Chief Financial Officer. Michael Tardugno, Executive Chairman, is also available for the question-and-answer portion of today's call. Before we begin, I'd like to remind everyone that our remarks today include forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include, but are not limited to, statements regarding the timing and enrollment of the company's clinical trials, the potential of the company's therapies to address unmet medical needs, the market potential for its product candidates, if approved, and the company's plans and expectations for its development programs. Words such as may, will, expect, plan, anticipate, estimate, and intend identify these forward-looking statements. Actual results may differ materially from those projected. Additional information on the factors that could cause actual results to differ is detailed in Imunon's filings with the Securities and Exchange Commission, which are available at sec.gov and on the company's website. The forward-looking statements made on this call speak only as of today's date, and the company undertakes no obligation to update them, except as required by law. With that, I'd now like to turn the call over to Dr. Stacy Lindborg, President and Chief Executive Officer. Stacy?

    Stacy Lindborg President and Chief Executive Officer Thank you, Valter, and good morning, everyone. Thank you for joining us today and for your continued support of Imunon. On our second quarter call in August, I said our priorities were clear: execute our Phase III OVATION-3 study, generate high-quality data, and deliver a much-needed therapy option for women with advanced ovarian cancer. The third quarter was a period in which we advanced all three, continued OVATION-3 enrollment, generated additional external validation of the data, and took further portfolio and capital structure actions. We recently hosted our 2026 R&D Day in New York City, where clinical investigators presented the full case for the Phase III IMNN-001 study in frontline ovarian cancer, which included the final Phase II overall survival results, the preliminary minimal residual disease findings, and the path to a confirmatory readout in OVATION-3. Our North Star remains unchanged: bringing a much-needed treatment option to women with advanced ovarian cancer, a disease that affects approximately 300,000 women worldwide each year, has five-year survival rates of approximately 41% for women diagnosed at Stage III and approximately 20% for women diagnosed at Stage IV, and has seen little advancement in frontline care, the standard of care for well over two decades.

    Frequently Asked Questions About IMNN

    When is Imunon's next earnings date?

    Imunon's next earnings report is expected for Mar 29, 2027.

    Did IMNN beat earnings estimates last quarter?

    Imunon reported EPS of -$0.64 for the quarter ended Sep 30, 2026, in line with the -$0.64 estimate.

    What EPS do analysts expect from IMNN next quarter?

    The consensus EPS estimate for Imunon for the quarter ending Dec 31, 2026 is -$0.51 from 7 analysts, with estimates from -$0.72 to -$0.25.

    How often does IMNN beat earnings estimates?

    Imunon beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +31.36%.